Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)Nicholas D. James, Jacob Tanguay, Gerhardt Attard et al.|International Journal of Cancer|2022Cited by 79
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programmeRuth E. Langley, Mahesh Parmar, Duncan C. Gilbert et al.|The Lancet|2021Cited by 49